vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and PATHWARD FINANCIAL, INC. (CASH). Click either name above to swap in a different company.
PATHWARD FINANCIAL, INC. is the larger business by last-quarter revenue ($276.3M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). PATHWARD FINANCIAL, INC. runs the higher net margin — 26.4% vs 11.1%, a 15.3% gap on every dollar of revenue. Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 21.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
ANIP vs CASH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $276.3M |
| Net Profit | $27.5M | $72.9M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 26.4% |
| Revenue YoY | 29.6% | — |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $3.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $276.3M | ||
| Q4 25 | $247.1M | $173.1M | ||
| Q3 25 | $227.8M | $186.7M | ||
| Q2 25 | $211.4M | $195.8M | ||
| Q1 25 | $197.1M | $274.8M | ||
| Q4 24 | $190.6M | $182.6M | ||
| Q3 24 | $148.3M | $179.5M | ||
| Q2 24 | $138.0M | $188.6M |
| Q1 26 | — | $72.9M | ||
| Q4 25 | $27.5M | $35.2M | ||
| Q3 25 | $26.6M | $38.8M | ||
| Q2 25 | $8.5M | $42.1M | ||
| Q1 25 | $15.7M | $75.0M | ||
| Q4 24 | $-10.3M | $30.0M | ||
| Q3 24 | $-24.2M | $33.5M | ||
| Q2 24 | $-2.3M | $44.9M |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 24.6% | ||
| Q3 25 | 15.9% | 25.9% | ||
| Q2 25 | 6.6% | 24.1% | ||
| Q1 25 | 13.3% | 33.2% | ||
| Q4 24 | -2.3% | 19.8% | ||
| Q3 24 | -13.8% | 20.9% | ||
| Q2 24 | 3.7% | 27.1% |
| Q1 26 | — | 26.4% | ||
| Q4 25 | 11.1% | 20.3% | ||
| Q3 25 | 11.7% | 20.8% | ||
| Q2 25 | 4.0% | 21.5% | ||
| Q1 25 | 8.0% | 27.3% | ||
| Q4 24 | -5.4% | 16.4% | ||
| Q3 24 | -16.3% | 18.7% | ||
| Q2 24 | -1.7% | 23.8% |
| Q1 26 | — | $3.35 | ||
| Q4 25 | $1.14 | $1.57 | ||
| Q3 25 | $1.13 | $1.69 | ||
| Q2 25 | $0.36 | $1.81 | ||
| Q1 25 | $0.69 | $3.14 | ||
| Q4 24 | $-0.45 | $1.23 | ||
| Q3 24 | $-1.27 | $1.34 | ||
| Q2 24 | $-0.14 | $1.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $157.6M |
| Total DebtLower is stronger | — | $59.5M |
| Stockholders' EquityBook value | $540.7M | $850.7M |
| Total Assets | $1.4B | $7.1B |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $157.6M | ||
| Q4 25 | $285.6M | $331.2M | ||
| Q3 25 | $262.6M | $120.6M | ||
| Q2 25 | $217.8M | $258.3M | ||
| Q1 25 | $149.8M | $254.2M | ||
| Q4 24 | $144.9M | $597.4M | ||
| Q3 24 | $145.0M | $158.3M | ||
| Q2 24 | $240.1M | $298.9M |
| Q1 26 | — | $59.5M | ||
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $33.5M | ||
| Q2 25 | — | $33.4M | ||
| Q1 25 | — | $33.4M | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | — | $33.3M |
| Q1 26 | — | $850.7M | ||
| Q4 25 | $540.7M | $854.5M | ||
| Q3 25 | $505.8M | $858.0M | ||
| Q2 25 | $436.8M | $819.0M | ||
| Q1 25 | $418.6M | $814.7M | ||
| Q4 24 | $403.7M | $758.3M | ||
| Q3 24 | $405.9M | $822.5M | ||
| Q2 24 | $455.8M | $748.4M |
| Q1 26 | — | $7.1B | ||
| Q4 25 | $1.4B | $7.6B | ||
| Q3 25 | $1.4B | $7.2B | ||
| Q2 25 | $1.3B | $7.2B | ||
| Q1 25 | $1.3B | $7.0B | ||
| Q4 24 | $1.3B | $7.6B | ||
| Q3 24 | $1.3B | $7.5B | ||
| Q2 24 | $920.8M | $7.5B |
| Q1 26 | — | 0.07× | ||
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $108.3M | ||
| Q3 25 | $44.1M | $303.7M | ||
| Q2 25 | $75.8M | $30.4M | ||
| Q1 25 | $35.0M | $188.3M | ||
| Q4 24 | $15.9M | $-71.7M | ||
| Q3 24 | $12.5M | $143.1M | ||
| Q2 24 | $17.4M | $113.2M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $104.1M | ||
| Q3 25 | $38.0M | $300.3M | ||
| Q2 25 | $71.8M | $27.7M | ||
| Q1 25 | $32.5M | $184.7M | ||
| Q4 24 | $13.5M | $-73.8M | ||
| Q3 24 | $7.7M | $138.8M | ||
| Q2 24 | $13.0M | $111.0M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 60.1% | ||
| Q3 25 | 16.7% | 160.9% | ||
| Q2 25 | 34.0% | 14.1% | ||
| Q1 25 | 16.5% | 67.2% | ||
| Q4 24 | 7.1% | -40.4% | ||
| Q3 24 | 5.2% | 77.3% | ||
| Q2 24 | 9.4% | 58.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.4% | ||
| Q3 25 | 2.7% | 1.8% | ||
| Q2 25 | 1.9% | 1.4% | ||
| Q1 25 | 1.3% | 1.3% | ||
| Q4 24 | 1.3% | 1.1% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 1.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 3.08× | ||
| Q3 25 | 1.66× | 7.83× | ||
| Q2 25 | 8.87× | 0.72× | ||
| Q1 25 | 2.23× | 2.51× | ||
| Q4 24 | — | -2.39× | ||
| Q3 24 | — | 4.27× | ||
| Q2 24 | — | 2.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
